Bone marrow transplantation for severe sickle cell anaemia.
Five children with sickle cell anaemia underwent bone marrow transplantation (BMT) for severe clinical disease. The conditioning regimen for BMT was in busulfan plus cyclophosphamide. The allograft contained more than 5 x 10(8) nucleated cells per kg recipient. Prophylaxis of GVHD consisted of methotrexate and cyclosporin A. Therapy was well tolerated. Duration of neutropenia (less than 0.5 x 10(9)/l) was short (14-25 d). Platelet recovery (greater than 50 x 10(9)/l) occurred between day 12 and 45. The patients have been followed up for 8-28 months. No major infections occurred and long-term BMT-related toxicity was limited to mild, chronic GVHD in one patient. Mean haemoglobin levels remained above 10 g/dl. Haemoglobin electrophoresis showed AS patterns in all grafted patients--all marrow donors having sickle cell trait. From our preliminary data, we conclude that BMT or sickle cell anaemia is curative, well tolerated and should be proposed for suitable patients.
Ferster
A
A
Hôpital Universitaire des Enfants Reine Fabiola, Free University of Brussels, Belgium.
De Valck
C
C
Azzi
N
N
Fondu
P
P
Toppet
M
M
Sariban
E
E
D000755:Anemia, Sickle Cell / Q000473:pathology / Q000628:therapy*; D016913:Blood Component Transfusion; D001853:Bone Marrow / Q000473:pathology; D016026:Bone Marrow Transplantation / Q000276:immunology* / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D006086:Graft vs Host Disease / Q000517:prevention & control; D006801:Humans; D007621:Karyotyping; D011379:Prognosis; D013997:Time Factors